Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMedOpen access

Kidney-Derived ECM Hydrogels as Cell Delivery Devices.

Rodrigues AM., Gimondi S., Quinteira R., Ferreira H., Martins A., Neves NM.

Laboratory Study on Chronic Kidney Disease, published in ACS Appl Mater Interfaces (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
ACS Appl Mater Interfaces (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
40062454
PMCID
PMC12772458
DOI
10.1021/acsami.4c15873
Citations
3

Abstract (original English)

Chronic kidney disease (CKD) represents a significant global health challenge, as emphasized by its increasing prevalence and limited treatment options. Stem cell-based therapies are promising alternatives for CKD treatment. In particular, adipose-derived mesenchymal stem cells (ASCs) have emerged as an attractive candidate cell source. However, challenges in optimizing stem cell delivery and survival upon implantation persist. The inclusion of stem cells in hydrogels addresses these challenges by providing mechanical support coupled to bioactive cues essential for kidney regeneration. In particular, hydrogels derived from a decellularized kidney extracellular matrix (dKECM) offer a biomimetic platform rich in native and important renal components. Herein, we investigate the performance of dKECM hydrogels with respect to the differentiation of ASCs toward kidney-specific phenotypes. First, dKECM hydrogels were characterized and compared with commercially available collagen I hydrogels, which are typically used for this therapeutic application. Subsequently, we evaluated the performance of encapsulated human ASCs and proximal tubular cells (HK-2 cell line), elucidating the impact of these hydrogels on their viability, metabolic activity, proliferation, morphology, and renal phenotype. Our findings highlight the superior potential of dKECM hydrogels in promoting a sustained cellu

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansHydrogelsMesenchymal Stem CellsExtracellular MatrixKidneyCell LineCell DifferentiationCell ProliferationCell SurvivalAdipose Tissue

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research